Xtandi (Enzalutamide): The 2027 Generic Opportunity Window

Astellas Pharma and Pfizer's blockbuster androgen receptor signaling inhibitor Xtandi (enzalutamide, over $5.2B in annual global sales) faces an imminent generic transition window. Its core composition-of-matter patent, US 7,709,517 ('Imidazolidine compounds'), expires on August 13, 2027 per the FDA Orange Book. No generic enzalutamide is commercially selling in the United States today; the market remains 100% brand-only. Major Indian generic manufacturers are actively positioned for commercial entry: Lupin Limited has received tentative FDA approval for generic enzalutamide tablets across 40mg, 80mg, 120mg, and 160mg strengths, while Sun Pharma, Cipla, Zydus Lifesciences, and Dr. Reddy's Laboratories maintain active Paragraph IV ANDA submissions. The multi-billion dollar oncology market opens to generic competitors upon patent expiry on August 13, 2027.